Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
820
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending March 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1 million
Operating profit¥-333 million operating loss
Ordinary income¥-321 million ordinary loss
Net income-317 Millions of yen quarterly net loss attributable to owners of the parent
Selling, general and administrative expenses{"value":334,"unit":"Millions of yen","売上高販管費率":"Not disclosed"}
Results for the three months of the current quarterRevenue of ¥1 million, operating loss of ¥333 million, ordinary loss of ¥321 million, and quarterly net loss attributable to owners of the parent of ¥317 million
Full-year earnings forecast
Net Sales
¥540 million
Operating loss
¥-1,030 million
Ordinary loss
¥-580 million
Net loss attributable to owners of the parent
¥-570 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net SalesCDMO business sales decline (¥83 million decrease)
Cost of salesSame as above (¥54 million decrease)
Selling, general and administrative expenses+¥107 million
Total research and development expenditure−¥24 million
Income from joint research and development+¥128 million
Net research and development expenses+¥103 million
Other SG&A expenses+¥3 million
Non-operating income+¥9 million
Non-Operating Expenses-¥5 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
ReHeart® reimbursement price¥53,200,000
Planned transplants in September-October 20262 cases
Post-marketing data collection within 3 yearsAt least 75 cases
New initiatives
- Launch of domestic sales of ReHeart® and commencement of transplants in September-October
- Joint development of cardiac muscle organoids with Asahi Intecc
- Completion of a pilot plant using a subsidy for the regenerative medicine CDMO business
- Research and development of large-scale cell culture technology
- Joint research with Stanford University on cardiac muscle sheets for overseas markets
- Negotiations on partnerships with overseas medical institutions and companies
Segment results
CDMO business: Sales decline stated. Segment revenue and profit figures are Not disclosedMarket Size / Share
Annual number of eligible patients in Japan with acute myocardial infarction and related conditions30,000 cases/year
Potential demand3,000 cases/year (assuming 10% of eligible patients)
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥1 million |
| Operating profit | ¥-333 million (operating loss) |
| Ordinary income | ¥-321 million (ordinary loss) |
| Net income | -317 Millions of yen (quarterly net loss attributable to owners of the parent) |
| Selling, general and administrative expenses | {"value":334,"unit":"Millions of yen","売上高販管費率":"Not disclosed"} |
| Results for the three months of the current quarter | Revenue of ¥1 million, operating loss of ¥333 million, ordinary loss of ¥321 million, and quarterly net loss attributable to owners of the parent of ¥317 million |
| Full-year earnings forecast | Net Sales ¥540 million / Operating loss ¥-1,030 million / Ordinary loss ¥-580 million / Net loss attributable to owners of the parent ¥-570 million |
| Segment results | CDMO business: Sales decline stated. Segment revenue and profit figures are Not disclosed |
| Breakdown of Factors Affecting the Change | Net Sales CDMO business sales decline (¥83 million decrease) / Cost of sales Same as above (¥54 million decrease) / Selling, general and administrative expenses +¥107 million / Total research and development expenditure −¥24 million / Income from joint research and development +¥128 million / Net research and development expenses +¥103 million / Other SG&A expenses +¥3 million / Non-operating income +¥9 million / Non-Operating Expenses -¥5 million |
| Assumptions Underlying the Business Outlook | ReHeart® reimbursement price ¥53,200,000 / Planned transplants in September-October 2026 2 cases / Post-marketing data collection within 3 years At least 75 cases |
| Market Size / Share | Annual number of eligible patients in Japan with acute myocardial infarction and related conditions 30,000 cases/year / Potential demand 3,000 cases/year (assuming 10% of eligible patients) |
| New initiatives | Launch of domestic sales of ReHeart® and commencement of transplants in September-October, Joint development of cardiac muscle organoids with Asahi Intecc, Completion of a pilot plant using a subsidy for the regenerative medicine CDMO business, Research and development of large-scale cell culture technology, Joint research with Stanford University on cardiac muscle sheets for overseas markets, Negotiations on partnerships with overseas medical institutions and companies |
Items this document does not state (17)
Gross Profit MarginOperating profit marginProgress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the first quarter, lower sales in the CDMO business reduced revenue, while the increase in net research and development expenses widened the operating loss. The upward revision to the full-year forecast reflects the inclusion of ReHeart®'s reimbursement price and cost of sales in the forecasts following approval of its reimbursement price, lower research and development expenses associated with ReHeart®'s approval, the end of a joint research agreement, and the expected receipt of a subsidy for the regenerative medicine CDMO business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.